Page last updated: 2024-10-29

ketorolac and Diabetes Mellitus

ketorolac has been researched along with Diabetes Mellitus in 3 studies

Ketorolac: A pyrrolizine carboxylic acid derivative structurally related to INDOMETHACIN. It is an NSAID and is used principally for its analgesic activity. (From Martindale The Extra Pharmacopoeia, 31st ed)
ketorolac : A racemate comprising equimolar amounts of (R)-(+)- and (S)-(-)-5-benzoyl-2,3-dihydro-1H-pyrrolizine-1-carboxylic acid. While only the (S)-(-) enantiomer is a COX1 and COX2 inhibitor, the (R)-(+) enantiomer exhibits potent analgesic activity. A non-steroidal anti-inflammatory drug, ketorolac is mainly used (generally as the tromethamine salt) for its potent analgesic properties in the short-term management of post-operative pain, and in eye drops to relieve the ocular itching associated with seasonal allergic conjunctivitis. It was withdrawn from the market in many countries in 1993 following association with haemorrhage and renal failure.
5-benzoyl-2,3-dihydro-1H-pyrrolizine-1-carboxylic acid : A member of the class of pyrrolizines that is 2,3-dihydro-1H-pyrrolizine which is substituted at positions 1 and 5 by carboxy and benzoyl groups, respectively.

Diabetes Mellitus: A heterogeneous group of disorders characterized by HYPERGLYCEMIA and GLUCOSE INTOLERANCE.

Research Excerpts

ExcerptRelevanceReference
"To evaluate the additional effect of ketorolac eye drops on therapeutic effects of intravitreal Bevacizumab in patients with diabetic macular edema (DME) METHODS: In a randomized clinical trial, 50 patients with center involved DME (macular thickness ≥ 300 microns accompanied by decreased VA (24 < BCVA ≤ 70 ETDRS letters) were enrolled consecutively and randomized 1:1 to receive either bevacizumab plus topical ketorolac (25 patients) or bevacizumab plus artificial tears (25 patients)."9.41Topical ketorolac as an adjunctive treatment with intravitreal bevacizumab in the management of diabetic macular edema: A double-masked placebo-controlled randomized clinical trial. ( Entezari, M; Hassanpour, K; Karimi, S; Niazpour Moez, R; Nikkhah, H; Ramezani, A; Yaseri, M, 2021)
"To evaluate the additional effect of ketorolac eye drops on therapeutic effects of intravitreal Bevacizumab in patients with diabetic macular edema (DME) METHODS: In a randomized clinical trial, 50 patients with center involved DME (macular thickness ≥ 300 microns accompanied by decreased VA (24 < BCVA ≤ 70 ETDRS letters) were enrolled consecutively and randomized 1:1 to receive either bevacizumab plus topical ketorolac (25 patients) or bevacizumab plus artificial tears (25 patients)."5.41Topical ketorolac as an adjunctive treatment with intravitreal bevacizumab in the management of diabetic macular edema: A double-masked placebo-controlled randomized clinical trial. ( Entezari, M; Hassanpour, K; Karimi, S; Niazpour Moez, R; Nikkhah, H; Ramezani, A; Yaseri, M, 2021)

Research

Studies (3)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's1 (33.33)24.3611
2020's2 (66.67)2.80

Authors

AuthorsStudies
Mohammad-Rabei, H1
Sabbaghi, H1
Emamverdi, M1
Karimi, S2
Ramezani, A2
Nikkhah, H2
Kheiri, B1
Yaseri, M2
Sheibani, K1
Bahreini, R1
Niazpour Moez, R1
Entezari, M1
Hassanpour, K1
Yılmaz, U1
Küçük, E1
Ulusoy, DM1
Özköse, A1
Ataş, M1
Demircan, S1
Yuvacı, I1

Trials

3 trials available for ketorolac and Diabetes Mellitus

ArticleYear
The effect of topical ketorolac tromethamine on macular thickening after phacoemulsification in diabetic patients.
    BMC ophthalmology, 2023, Jul-14, Volume: 23, Issue:1

    Topics: Diabetes Mellitus; Diabetic Retinopathy; Humans; Ketorolac; Ketorolac Tromethamine; Macular Edema; P

2023
Topical ketorolac as an adjunctive treatment with intravitreal bevacizumab in the management of diabetic macular edema: A double-masked placebo-controlled randomized clinical trial.
    Graefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie, 2021, Volume: 259, Issue:10

    Topics: Angiogenesis Inhibitors; Bevacizumab; Diabetes Mellitus; Diabetic Retinopathy; Humans; Intravitreal

2021
The assessment of changes in macular thickness in diabetic and non-diabetic patients: the effect of topical ketorolac on macular thickness change after ND:YAG laser capsulotomy.
    Cutaneous and ocular toxicology, 2016, Volume: 35, Issue:1

    Topics: Administration, Topical; Adult; Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Ca

2016
chemdatabank.com